

# François Guilhot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1063597/publications.pdf>

Version: 2024-02-01

51  
papers

17,871  
citations

186265

28  
h-index

189892

50  
g-index

52  
all docs

52  
docs citations

52  
times ranked

9880  
citing authors

#	ARTICLE	IF	CITATIONS
1	Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2003, 348, 994-1004.	27.0	3,227
2	Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2006, 355, 2408-2417.	27.0	3,212
3	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , 2013, 122, 872-884.	1.4	1,743
4	Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. <i>Lancet Oncology</i> , The, 2010, 11, 1029-1035.	10.7	1,359
5	Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2009, 27, 6041-6051.	1.6	1,188
6	Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. <i>Blood</i> , 2002, 99, 1928-1937.	1.4	943
7	Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2017, 376, 917-927.	27.0	926
8	Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. <i>Blood</i> , 2008, 111, 4022-4028.	1.4	565
9	Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia. <i>New England Journal of Medicine</i> , 1997, 337, 223-229.	27.0	549
10	Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. <i>Lancet Oncology</i> , The, 2018, 19, 747-757.	10.7	444
11	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. <i>Blood</i> , 2007, 109, 3207-3213.	1.4	400
12	Ponatinib efficacy and safety in Philadelphia chromosomeâ€“positive leukemia: final 5-year results of the phase 2 PACE trial. <i>Blood</i> , 2018, 132, 393-404.	1.4	392
13	Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2010, 363, 2511-2521.	27.0	362
14	Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease. <i>Journal of Clinical Oncology</i> , 2014, 32, 424-430.	1.6	355
15	Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. <i>Blood</i> , 2007, 109, 4143-4150.	1.4	352
16	Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 424-430.	1.6	265
17	Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. <i>Blood</i> , 2014, 123, 1353-1360.	1.4	231
18	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 612-621.	10.7	214

#	ARTICLE	IF	CITATIONS
19	Survival advantage from imatinib compared with the combination interferon- $\gamma$ plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood, 2006, 108, 1478-1484.	1.4	210
20	Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica, 2017, 102, 1368-1377.	3.5	114
21	Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer, 2009, 115, 551-560.	4.1	108
22	Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica, 2012, 97, 731-738.	3.5	103
23	Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. Journal of the National Cancer Institute, 2016, 108, djw003.	6.3	82
24	Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood, 2012, 119, 5963-5971.	1.4	69
25	Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood, 2003, 102, 4298-4305.	1.4	59
26	High rates of durable response are achieved with imatinib after treatment with interferon $\gamma$ plus cytarabine: results from the International Randomized Study of Interferon and ST1571 (IRIS) trial. Haematologica, 2009, 94, 1669-1675.	3.5	45
27	BCR-ABL $\gamma$ -Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients. Cancer Research, 2014, 74, 2669-2676.	0.9	44
28	Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. Blood, 2014, 124, 3135-3135.	1.4	43
29	Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML. Cancer Research, 2020, 80, 2394-2406.	0.9	30
30	Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML). Blood, 2014, 124, 519-519.	1.4	30
31	Interferon therapy in chronic myelogenous leukemia. Hematology/Oncology Clinics of North America, 2004, 18, 585-603.	2.2	27
32	Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients. European Journal of Immunology, 2012, 42, 1870-1875.	2.9	24
33	Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study. Cancer, 2020, 126, 3438-3447.	4.1	20
34	Tolerability and efficacy of pegylated interferon- $\gamma$ 2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia. Cancer, 2013, 119, 4284-4289.	4.1	16
35	Interferon in chronic myeloid leukaemia: past and future. Best Practice and Research in Clinical Haematology, 2009, 22, 315-329.	1.7	15
36	Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. Leukemia, 2021, 35, 2332-2345.	7.2	15

#	ARTICLE	IF	CITATIONS
37	Immunotherapeutic approaches in chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 629-634.	1.3	11
38	Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches. <i>BioDrugs</i> , 2017, 31, 143-149.	4.6	11
39	Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC). <i>Blood</i> , 2015, 126, 134-134.	1.4	10
40	The Rho-ROCK pathway as a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia. <i>Journal of Pathology</i> , 2016, 240, 262-268.	4.5	9
41	Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial. <i>Blood</i> , 2013, 122, 1498-1498.	1.4	8
42	Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial. <i>Blood</i> , 2013, 122, 650-650.	1.4	8
43	Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials. <i>Blood</i> , 2014, 124, 4552-4552.	1.4	8
44	11q13 Rearrangement in B Cell Chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 1997, 25, 539-543.	1.3	6
45	Beyond tyrosine kinase inhibitors: Combinations and other agents. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 271-283.	1.7	5
46	Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2018, 59, 766-769.	1.3	4
47	Long Term Outcome of Chronic Phase Chronic Myeloid Leukemia (CP CML) Patients (pts) from the French Spirit Study Comparing Imatinib (IM) 400 Mg to Higher Dose Imatinib or Combination with Peg-interferon $\alpha$ 2a (PegIFN) or Cytarabine (Ara-C) : A Trial of the FI LMC (France intergroupe de la Tj ETQq1 1 0.784314 rgBT/Overlook	1.4	4
48	Ponatinib and platelets a conflict in CML. <i>Blood</i> , 2019, 133, 1520-1521.	1.4	3
49	Dasatinib regimens for patients with chronic myeloid leukemia. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 680-682.	27.6	2
50	Achieving Early Landmark Response Is Predictive of Outcomes in Heavily Pretreated Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib. <i>Blood</i> , 2014, 124, 518-518.	1.4	1
51	Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation. <i>Blood</i> , 2016, 128, 3067-3067.	1.4	0